<p>Checkpoint Therapeutics, Inc.（纳斯达克代码：CKPT - 获取免费报告）在 5 月份的空头头寸大幅下降。截至 5 月 15 日，空头头寸总计为 2,960,000 股，比 4 月 30 日的 3,800,000 股下降了 22.1%。该公司约有 6.2% 的股票被做空。根据平均每日成交量 2,690,000 股，目前的空头头寸比率为 1.1 天。</p>
<h2>Checkpoint Therapeutics 的内部交易</h2>
<p>在其他消息中，首席执行官 James F. Oliviero III 于 4 月 2 日星期三出售了 15,090 股公司的股票，交易价格为每股平均 4.04 美元，总交易额为 60,963.60 美元。交易后，首席执行官现在直接拥有 3,759,929 股公司的股票，估值约为 15,190,113.16 美元。这笔交易代表其持股比例下降了 0.40%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站获取。此外，首席财务官 William Garrett Gray 于 4 月 1 日星期二出售了 12,322 股公司的股票，交易价格为每股平均 4.05 美元，总交易额为 49,904.10 美元。出售后，首席财务官现在拥有 1,446,322 股公司的股票，估值为 5,857,604.10 美元。这笔交易代表其持股比例下降了 0.84%。该出售的披露信息可以在此找到。内部人士持有公司 2.10% 的股票。</p>
<h2>机构资金流入和流出</h2>
<p>大型投资者最近增加或减少了对该股票的持股。SBI 证券有限公司在第四季度购买了 Checkpoint Therapeutics 的新股份，价值 32,000 美元。Tower Research Capital LLC TRC 在第四季度将其在 Checkpoint Therapeutics 的持股增加了 157.0%。Tower Research Capital LLC TRC 现在拥有 10,616 股公司的股票，价值 34,000 美元，此前在上个季度购买了 6,486 股。Virtu Financial LLC 在第四季度将其在 Checkpoint Therapeutics 的持股增加了 180.5%。Virtu Financial LLC 现在拥有 38,157 股公司的股票，价值 122,000 美元，此前在上个季度购买了 24,552 股。Stifel Financial Corp 在第四季度购买了 Checkpoint Therapeutics 的新股份，价值约 32,000 美元。最后，Raymond James Financial Inc.在第四季度收购了 Checkpoint Therapeutics 的新股份，价值约 67,000 美元。机构投资者和对冲基金持有公司 22.00% 的股票。</p>
<h2>Checkpoint Therapeutics 的价格表现</h2>
<p>纳斯达克代码：CKPT 的股票周一开盘价为 4.26 美元。该公司的 50 日移动平均线为 4.09 美元，200 日移动平均线为 3.68 美元。该公司的市值为 3.7071 亿美元，市盈率为-2.32，贝塔值为 1.18。Checkpoint Therapeutics 的 12 个月低点为 1.80 美元，12 个月高点为 4.50 美元。</p>
<p>Checkpoint Therapeutics（纳斯达克代码：CKPT - 获取免费报告）最近一次发布财报是在 5 月 13 日星期二。公司报告本季度每股收益为（0.19 美元），低于分析师一致预期的（0.10 美元），差距为（0.09 美元）。股票研究分析师预计 Checkpoint Therapeutics 在本年度将发布-0.94 的每股收益。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票研究分析师最近对该公司发表了看法。D. Boral Capital 在 3 月 31 日的研究报告中重申了 “买入” 评级，并设定了 4.80 美元的目标价。Lake Street Capital 在 3 月 10 日的研究报告中重申了 “持有” 评级，并将 Checkpoint Therapeutics 的目标价下调至 4.10 美元（之前为 7.00 美元）。最后，HC Wainwright 在 3 月 11 日的报告中重申了 “中性” 评级，并设定了 4.10 美元的目标价。</p>
<p><strong>阅读我们对 Checkpoint Therapeutics 的最新分析</strong></p>
<h2>关于 Checkpoint Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Checkpoint Therapeutics, Inc.是一家临床阶段的免疫疗法和靶向肿瘤学公司，专注于在美国和国际上获取、开发和商业化新型治疗方案，以治疗实体肿瘤癌症患者。该公司的主要抗体产品候选药物是 Cosibelimab，目前正在进行针对特定复发或转移性癌症患者的 1 期临床试验；CK-302 是一个针对血液恶性肿瘤和实体肿瘤的预临床试验产品候选药物。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Checkpoint Therapeutics</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>为什么 Dollar General 可能是零售业最被低估的反弹股</li>
<li>纽约证券交易所股票为投资者提供多种优质选择</li>
<li>3 种聪明的方式参与加密货币热潮——无需购买币</li>
<li>外汇是什么，如何运作？</li>
<li>3 家评级最高的能源公司正在强劲复苏</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Checkpoint Therapeutics 吗？</h2>
<p>在考虑 Checkpoint Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Checkpoint Therapeutics 并不在名单上。</p>
<p>虽然 Checkpoint Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Checkpoint医疗

<p>Checkpoint Therapeutics, Inc.（纳斯达克代码：CKPT）在 5 月份的空头头寸下降了 22.1%，总计为 2,960,000 股。目前，6.2% 的股份被做空，覆盖天数比率为 1.1 天。首席执行官 James F. Oliviero III 和首席财务官 William Garrett Gray 最近出售了股份，减少了他们的持股比例。机构投资者持有 22% 的股票。该公司的股票开盘价为 4.26 美元，市值为 3.7071 亿美元。分析师的评级各不相同，目标价格范围在 4.10 美元到 4.80 美元之间</p>

<p>Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) saw a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 2,960,000 shares, a decline of 22.1% from the April 30th total of 3,800,000 shares. Approximately 6.2% of the company's stock are short sold. Based on an average daily volume of 2,690,000 shares, the short-interest ratio is currently 1.1 days.</p>
<div class="lb-trans"><p>Checkpoint Therapeutics, Inc.（纳斯达克代码：CKPT - 获取免费报告）在 5 月份的空头头寸大幅下降。截至 5 月 15 日，空头头寸总计为 2,960,000 股，比 4 月 30 日的 3,800,000 股下降了 22.1%。该公司约有 6.2% 的股票被做空。根据平均每日成交量 2,690,000 股，目前的空头头寸比率为 1.1 天。</p>
</div><h2>Insider Transactions at Checkpoint Therapeutics</h2>
<div class="lb-trans"><h2>Checkpoint Therapeutics 的内部交易</h2>
</div><p>In other news, CEO James F. Oliviero III sold 15,090 shares of the firm's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $4.04, for a total transaction of $60,963.60. Following the transaction, the chief executive officer now directly owns 3,759,929 shares of the company's stock, valued at approximately $15,190,113.16. This trade represents a 0.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, CFO William Garrett Gray sold 12,322 shares of the business's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $4.05, for a total transaction of $49,904.10. Following the sale, the chief financial officer now owns 1,446,322 shares in the company, valued at $5,857,604.10. This trade represents a 0.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席执行官 James F. Oliviero III 于 4 月 2 日星期三出售了 15,090 股公司的股票，交易价格为每股平均 4.04 美元，总交易额为 60,963.60 美元。交易后，首席执行官现在直接拥有 3,759,929 股公司的股票，估值约为 15,190,113.16 美元。这笔交易代表其持股比例下降了 0.40%。该出售在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站获取。此外，首席财务官 William Garrett Gray 于 4 月 1 日星期二出售了 12,322 股公司的股票，交易价格为每股平均 4.05 美元，总交易额为 49,904.10 美元。出售后，首席财务官现在拥有 1,446,322 股公司的股票，估值为 5,857,604.10 美元。这笔交易代表其持股比例下降了 0.84%。该出售的披露信息可以在此找到。内部人士持有公司 2.10% 的股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Large investors have recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. purchased a new stake in shares of Checkpoint Therapeutics during the fourth quarter worth $32,000. Tower Research Capital LLC TRC increased its position in Checkpoint Therapeutics by 157.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company's stock worth $34,000 after purchasing an additional 6,486 shares during the last quarter. Virtu Financial LLC raised its stake in shares of Checkpoint Therapeutics by 180.5% during the 4th quarter. Virtu Financial LLC now owns 38,157 shares of the company's stock worth $122,000 after purchasing an additional 24,552 shares in the last quarter. Stifel Financial Corp purchased a new stake in shares of Checkpoint Therapeutics during the 4th quarter worth about $32,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Checkpoint Therapeutics during the 4th quarter valued at about $67,000. Institutional investors and hedge funds own 22.00% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对该股票的持股。SBI 证券有限公司在第四季度购买了 Checkpoint Therapeutics 的新股份，价值 32,000 美元。Tower Research Capital LLC TRC 在第四季度将其在 Checkpoint Therapeutics 的持股增加了 157.0%。Tower Research Capital LLC TRC 现在拥有 10,616 股公司的股票，价值 34,000 美元，此前在上个季度购买了 6,486 股。Virtu Financial LLC 在第四季度将其在 Checkpoint Therapeutics 的持股增加了 180.5%。Virtu Financial LLC 现在拥有 38,157 股公司的股票，价值 122,000 美元，此前在上个季度购买了 24,552 股。Stifel Financial Corp 在第四季度购买了 Checkpoint Therapeutics 的新股份，价值约 32,000 美元。最后，Raymond James Financial Inc.在第四季度收购了 Checkpoint Therapeutics 的新股份，价值约 67,000 美元。机构投资者和对冲基金持有公司 22.00% 的股票。</p>
</div><h2>Checkpoint Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Checkpoint Therapeutics 的价格表现</h2>
</div><p>Shares of NASDAQ:CKPT opened at $4.26 on Monday. The company's fifty day moving average is $4.09 and its two-hundred day moving average is $3.68. The company has a market cap of $370.71 million, a P/E ratio of -2.32 and a beta of 1.18. Checkpoint Therapeutics has a 12-month low of $1.80 and a 12-month high of $4.50.</p>
<div class="lb-trans"><p>纳斯达克代码：CKPT 的股票周一开盘价为 4.26 美元。该公司的 50 日移动平均线为 4.09 美元，200 日移动平均线为 3.68 美元。该公司的市值为 3.7071 亿美元，市盈率为-2.32，贝塔值为 1.18。Checkpoint Therapeutics 的 12 个月低点为 1.80 美元，12 个月高点为 4.50 美元。</p>
</div><p>Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.09). Equities research analysts anticipate that Checkpoint Therapeutics will post -0.94 earnings per share for the current year.</p>
<div class="lb-trans"><p>Checkpoint Therapeutics（纳斯达克代码：CKPT - 获取免费报告）最近一次发布财报是在 5 月 13 日星期二。公司报告本季度每股收益为（0.19 美元），低于分析师一致预期的（0.10 美元），差距为（0.09 美元）。股票研究分析师预计 Checkpoint Therapeutics 在本年度将发布-0.94 的每股收益。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities research analysts have recently weighed in on the company. D. Boral Capital reissued a &#34;buy&#34; rating and set a $4.80 price objective on shares of Checkpoint Therapeutics in a research note on Monday, March 31st. Lake Street Capital reiterated a &#34;hold&#34; rating and issued a $4.10 price target (down previously from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th. Finally, HC Wainwright restated a &#34;neutral&#34; rating and set a $4.10 price objective on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该公司发表了看法。D. Boral Capital 在 3 月 31 日的研究报告中重申了 “买入” 评级，并设定了 4.80 美元的目标价。Lake Street Capital 在 3 月 10 日的研究报告中重申了 “持有” 评级，并将 Checkpoint Therapeutics 的目标价下调至 4.10 美元（之前为 7.00 美元）。最后，HC Wainwright 在 3 月 11 日的报告中重申了 “中性” 评级，并设定了 4.10 美元的目标价。</p>
</div><p><strong>Read Our Latest Analysis on Checkpoint Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 Checkpoint Therapeutics 的最新分析</strong></p>
</div><h2>About Checkpoint Therapeutics</h2>
<div class="lb-trans"><h2>关于 Checkpoint Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.</p>
<div class="lb-trans"><p>Checkpoint Therapeutics, Inc.是一家临床阶段的免疫疗法和靶向肿瘤学公司，专注于在美国和国际上获取、开发和商业化新型治疗方案，以治疗实体肿瘤癌症患者。该公司的主要抗体产品候选药物是 Cosibelimab，目前正在进行针对特定复发或转移性癌症患者的 1 期临床试验；CK-302 是一个针对血液恶性肿瘤和实体肿瘤的预临床试验产品候选药物。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Checkpoint Therapeutics</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>Why Dollar General May Be Retail’s Most Undervalued Rebound</li>
<li>NYSE Stocks Give Investors a Variety of Quality Options</li>
<li>3 Smart Ways to Play the Crypto Boom—No Coins Needed</li>
<li>What is Forex and How Does it Work?</li>
<li>3 Top-Rated Energy Companies Staging Strong Recoveries</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Checkpoint Therapeutics</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>为什么 Dollar General 可能是零售业最被低估的反弹股</li>
<li>纽约证券交易所股票为投资者提供多种优质选择</li>
<li>3 种聪明的方式参与加密货币热潮——无需购买币</li>
<li>外汇是什么，如何运作？</li>
<li>3 家评级最高的能源公司正在强劲复苏</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Checkpoint Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Checkpoint Therapeutics 吗？</h2>
</div><p>Before you consider Checkpoint Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Checkpoint Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Checkpoint Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Checkpoint Therapeutics 并不在名单上。</p>
</div><p>While Checkpoint Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Checkpoint Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Checkpoint Therapeutics, Inc.（纳斯达克代码：CKPT）的空头头寸减少了 22.1%